Relay Therapeutics Stock In The News
| RLAY Stock | USD 4.86 0.11 2.32% |
Our overall analysis of Relay Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Relay Therapeutics. The specific impact of Relay Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Relay Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Relay Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Relay Therapeutics Backtesting and Relay Therapeutics Hype Analysis. For more information on how to buy Relay Stock please use our How to Invest in Relay Therapeutics guide.
Relay |
Relay Therapeutics Today Top News and Investor Outlook
Relay Therapeutics Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Relay and other traded companies coverage with news coverage. We help investors stay connected with Relay headlines for the 26th of November to make an informed investment decision based on correlating the impacts of news items on Relay Stock performance. Please note that trading solely based on the Relay Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Relay Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Relay earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Relay Therapeutics that are available to investors today. That information is available publicly through Relay media outlets and privately through word of mouth or via Relay internal channels. However, regardless of the origin, that massive amount of Relay data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Relay Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Relay Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Relay Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Relay Therapeutics alpha.
Relay Largest EPS Surprises
Earnings surprises can significantly impact Relay Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-02 | 2024-03-31 | -0.7 | -0.62 | 0.08 | 11 | ||
2022-08-04 | 2022-06-30 | -0.63 | -0.71 | -0.08 | 12 | ||
2023-05-04 | 2023-03-31 | -0.69 | -0.78 | -0.09 | 13 | ||
2024-11-06 | 2024-09-30 | -0.77 | -0.63 | 0.14 | 18 | ||
2023-02-23 | 2022-12-31 | -0.7 | -0.56 | 0.14 | 20 | ||
2020-11-12 | 2020-09-30 | -0.35 | -0.51 | -0.16 | 45 |
Relay Therapeutics Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Relay Therapeutics Stock. Current markets are strongly bullish. About 75% of major world exchanges and indexes are currently up. See today's market update for more information.
25th of November 2024
Disposition of 19864 shares by Peter Rahmer of Relay Therapeutics at 6.47 subject to Rule ... at MacroaxisInsider
19th of November 2024
Down -23.95 percent in 4 Weeks, Heres Why Relay Therapeutics Looks Ripe for a Turnaround at zacks.com
13th of November 2024
Relay Therapeutics SWOT analysis PI3K inhibitor progress fuels stock potential at investing.com
6th of November 2024
Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights at globenewswire.com
30th of October 2024
Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highligh... at globenewswire.com
28th of October 2024
Disposition of 1632 shares by Adams Brian of Relay Therapeutics at 6.06 subject to Rule 16... at finance.yahoo.com
14th of October 2024
Relay Therapeutics Receives Buy Rating from HC Wainwright at thelincolnianonline.com
1st of October 2024
Relay Therapeutics executive sells shares worth over 4,800 at investing.com
30th of September 2024
Driehaus Capital Management LLC Purchases 218,302 Shares of Relay Therapeutics, Inc. - Mar... at news.google.com
23rd of September 2024
Disposition of 1657 shares by Peter Rahmer of Relay Therapeutics at 11.16 subject to Rule ... at MacroaxisInsider
10th of September 2024
Relay upgraded by Jefferies, downgraded by Oppenheimer at seekingalpha.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Relay Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Relay Therapeutics' short interest history, or implied volatility extrapolated from Relay Therapeutics options trading.
Additional Tools for Relay Stock Analysis
When running Relay Therapeutics' price analysis, check to measure Relay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relay Therapeutics is operating at the current time. Most of Relay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relay Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relay Therapeutics' price. Additionally, you may evaluate how the addition of Relay Therapeutics to your portfolios can decrease your overall portfolio volatility.